GLP Watchdog
FDA-Approved MedicationUpdated August 14, 2026

Ozempic Guide

Ozempic is the brand-name formulation of semaglutide FDA-approved for type 2 diabetes management, though it has become widely prescribed off-label for weight loss. It is available in doses of 0.5mg, 1mg, and 2mg weekly, and is manufactured by Novo Nordisk. Ozempic also carries an FDA indication to reduce cardiovascular risk in adults with type 2 diabetes and heart disease.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed

At a Glance

Generic NameSemaglutide
Brand NamesOzempic
FDA StatusFDA-approved for glycemic control in type 2 diabetes (December 2017); FDA-approved to reduce cardiovascular risk in adults with T2DM and established CVD (2020). Weight loss is off-label use.[1]
Approval DateDecember 5, 2017[1]

How Ozempic Works

Ozempic activates GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, and reduce blood sugar levels. The same mechanism that controls blood glucose also suppresses appetite and slows gastric emptying, producing significant weight loss as a secondary effect. At 1–2mg doses, Ozempic delivers strong appetite suppression comparable to Wegovy's lower dose range.[2][3]

Dosing Schedule

Ozempic uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].

Weeks 1–40.25mg/week
Weeks 5+0.5mg/week
After 4+ weeks at 0.5mg1mg/week (if needed)
After 4+ weeks at 1mg2mg/week (max)

Side Effects

Common: nausea, vomiting, diarrhea, stomach pain, constipation. Injection site reactions are common in early weeks. Serious (rare): pancreatitis, diabetic retinopathy worsening, kidney injury, hypoglycemia when combined with sulfonylureas or insulin. Thyroid C-cell tumor risk noted in animal studies.[1][2]

This is not a complete list. Consult your healthcare provider or prescriber for full safety information. The complete adverse reaction profile is published in the current FDA prescribing information[1].

Clinical Trial Results

In the SUSTAIN-6 cardiovascular trial, Ozempic reduced the risk of major cardiovascular events by 26% vs. placebo (Marso et al. NEJM 2016, PMID 27633186). For weight loss specifically, the STEP-8 head-to-head trial (Rubino et al. JAMA 2022, PMID 34962517) used semaglutide 2.4 mg — the Wegovy dose, not the Ozempic 1 mg dose — and showed 15.8% weight loss vs 6.4% for liraglutide 3 mg. Ozempic itself is FDA-approved only for type 2 diabetes; Wegovy is the FDA-approved semaglutide for chronic weight management.[2]

Source: Published clinical trial data (STEP / SURMOUNT trial series) — see the Sources panel below for full citations.

Where to Get Ozempic

These telehealth providers offer access to semaglutide or compounded equivalents with online consultations and home delivery.

8.8/ 10
Verified partner

Gala

Best for: moving between compounded and brand without changing seller

★★★★☆4.4/5

Editorial score · methodology

$129/mo
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full Gala review →
8.4/ 10

Vaylen

Best for: bloodwork inside the $179/month rather than billed on top

★★★★☆4.2/5

Editorial score · methodology

$179/mo
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full Vaylen review →
8.3/ 10

Navio MD

Best for: moving between compounded and brand without changing seller

★★★★☆4.2/5

Editorial score · methodology

$189/mo
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full Navio MD review →
8.2/ 10

Effecty

Best for: moving between compounded and brand without changing seller

★★★★☆4.1/5

Editorial score · methodology

$60/mo
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full Effecty review →
7.9/ 10

GOAL.MD

Best for: starting below a standard dose, with microdose tiers

★★★★☆4/5

Editorial score · methodology

$179/mo
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full GOAL.MD review →
7.7/ 10

NuuVim

Best for: semaglutide at $79/month, 58% under the register median

★★★★☆3.9/5

Editorial score · methodology

$79/mo
CompoundedSemaglutideTirzepatideLegitScript VerifiedFDA Warning
Get StartedRead full NuuVim review →

Cost Comparison

Ozempic cost & pricing →Savings & coupons →Dosing & titration →How to get it →Storage & handling →Alternatives →Manufacturer coupon →

Starting prices for compounded GLP-1 medications from top providers, sorted cheapest first. Compounded semaglutide from licensed 503A and 503B pharmacies is legal under federal compounding law[4], with additional tolerances historically allowed while the molecule has appeared on the FDA Drug Shortage List[5]. Both compounded and brand-name prescriptions are generally FSA/HSA eligible under IRS Publication 502[6]. Prices may vary based on dose and promo availability.

ProviderStarting Price
AM Rx$25/moVisit
Calibrate Health$25/moVisit
FitRx$25/moVisit
Roen Rx$25/moVisit
Evernow$49/moVisit
GOAL.MD$244/moVisit
Cost Plus Drugs$279/moVisit
Navio MD$345/moVisit
Vital Edge$705/moVisit
Modern Age$900/moVisit
Push Health$950/moVisit
Vaylen$997/moVisit
altRX$1149/moVisit
Levity$1199/moVisit
Healthicare$1200/moVisit
Aquivia Health$1299/moVisit
Gala$1299/moVisit
Luvo Health$1299/moVisit
RxSpan MD$1299/moVisit
Effecty$1300/moVisit
Ark Health$1399/moVisit
Better U Care$1399/moVisit
Elevated Health$1399/moVisit
Eve$1399/moVisit
NuuVim$1498/moVisit
Superpower$1799/moVisit
Concierge MD LA$1999/moVisit

Ozempic Head-to-Head Comparisons

Short-form verdict pages comparing Ozempic to other GLP-1 options with trial-anchored data, FDA-label dosing, and current manufacturer pricing.

Ozempic vs Mounjaro
Two diabetes drugs prescribed off-label for weight. SURPASS-2 compared them directly at 40 weeks — 11.2 kg against 5.7 kg — but only Ozempic has finished a cardiovascular outcomes trial.
Last verified 2026-05-27
Ozempic vs Rybelsus
The same molecule from the same maker, as a daily tablet and a weekly injection. Only about 1% of the tablet gets in — which explains almost every difference between them.
Last verified 2026-05-27
Ozempic vs Zepbound
Different molecules, different labels, and a head-to-head that favors one clearly: 20.2% against 13.7% at 72 weeks in SURMOUNT-5.
Last verified 2026-05-27
Ozempic vs Wegovy
The same molecule from the same maker under two names, with two labels, two dose ceilings and two entirely different coverage stories. This confusion costs people money every day.
Last verified 2026-05-27
Ozempic vs Foundayo
A weekly diabetes injection with proven cardiac benefit against a daily weight pill approved April 2026. Each holds exactly what the other lacks.
Last verified 2026-05-27
Ozempic vs Trulicity
Two weekly diabetes injections, tested directly against each other. Ozempic wins on blood sugar and weight; Trulicity holds the broader cardiac indication and the pediatric one.
Last verified 2026-05-28

See all drug-vs-drug verdicts.

Pivotal Ozempic Trial Walkthroughs

Endpoint-by-endpoint breakdowns of the trials that shaped the Ozempic label, with primary-source numbers and FAQs.

SUSTAIN-6
SUSTAIN-6 was designed as a safety trial and returned a benefit. Across a median 2.1 years, in 3,297 people whose diabetes came with high cardiac risk, the three-part endpoint hit 6.6% of the semaglutide group and 8.9% of the placebo group. It established the cardiovascular signal that SELECT would later confirm in a population without diabetes, and it is the trial behind Ozempic's cardiovascular labeling.
Phase 3 · N=3,297 · Last verified 2026-05-28
FLOW
FLOW asked whether semaglutide slows kidney disease, in 3,533 people whose type 2 diabetes had damaged their kidneys, tracked for a median 3.4 years. The composite outcome — kidney failure, sustained eGFR decline, or renal or cardiovascular death — occurred in 18.7% against 23.2% on placebo, a 24% relative reduction. The independent monitoring committee stopped it early because the benefit was clear enough that continuing the placebo arm was no longer justified.
Phase 3b · N=3,533 · Last verified 2026-05-28
SUSTAIN-7
SUSTAIN-7 compared semaglutide against dulaglutide head-to-head at matched dose levels in 1,201 people living with type 2 diabetes across 40 weeks. Semaglutide 0.5 mg lowered HbA1c 1.5 points against dulaglutide 0.75 mg's 1.1, with the same direction at the higher pairing, and produced more weight loss at both. It is one of the few direct comparisons between two weekly GLP-1s and it settled which is the more potent.
Phase 3b · N=1,201 · Last verified 2026-05-28

Ozempic Patient Questions, Answered

Real patient questions about Ozempic pulled from named subreddits and answered with peer-reviewed trial data.

GLP-1 Coverage: the 10 Questions People Ask After a Denial
10 questions · 12 PubMed citations
Last verified 2026-05-28

Ozempic Reference Cards

Scannable cheat sheets for dose schedules, missed-dose rules, and red-flag side effects — every number verified against the DailyMed FDA label.

Missed an Ozempic Dose? The Five-Day Window Explained
Ozempic's forgiveness window is five days from the day the shot was due, which is longer than the four-day window on tirzepatide — one reason applying a rule learned on another GLP-1 gets people into trouble. This page covers the decision, the 48-hour minimum between any two injections, and the far murkier question of what to do when the gap has run to weeks rather than days.
4 min read · Last verified 2026-05-27
GLP-1 Injection Sites: Rotation, Technique and the Lump to Avoid
Every weekly GLP-1 permits the same three injection sites and every one of them tells you to move around. The reason is a lump called lipohypertrophy — thickened fat that soaks up the drug at an unpredictable rate. When absorption becomes erratic so does appetite suppression, and a stalled month gets blamed on the dose when the cause is a favorite square inch of belly.
4 min read · Last verified 2026-05-28
Switching Between GLP-1s: Why You Start at the Bottom Again
Switching is common — a formulary changes, side effects bite, or you reach the top of a ladder with weight still to lose — and no label tells you how to do it. The rule that surprises people is that you go back to the bottom even though you have been on a GLP-1 for a year. Tolerating one of these drugs does not buy you tolerance of another, because they do not act on the same receptors.
5 min read · Last verified 2026-05-28

Ranked PubMed Studies on Ozempic

Curated lists of the highest-impact peer-reviewed studies on Ozempic and related GLP-1 drugs. Every PMID live-verified via PubMed esummary.

The 10 Semaglutide Weight-Loss Trials That Matter (2026)
Semaglutide has been tested more thoroughly for weight than any drug before it, and the ten trials below are the ones that changed something: the dose we use, the label it carries, what happens when you stop, and whether it does anything beyond the scale. Each entry gives the PMID, the design, and the figure that mattered.
10 ranked papers · Last verified 2026-08-16
The 10 Cardiovascular Outcome Trials Behind the GLP-1 Class (2026)
The cardiovascular evidence for this class is now broad enough to compare with statins: more than 80,000 patients across ten major trials. These are the ones that changed a label or a guideline — plus ELIXA, which found no benefit at all and remains the most useful negative result in the field.
10 ranked papers · Last verified 2026-08-16
The 10 Kidney Trials Behind the GLP-1 Class (2026)
For most of the last decade the kidney case for these drugs was assembled from secondary endpoints inside trials designed to measure something else. FLOW finally tested it directly in 2024 and produced the first kidney label in the class. These are that trial and the nine analyses that made anyone think it was worth running.
10 ranked papers · Last verified 2026-08-16
Every Published Retatrutide Trial (2026): the 24.2% Drug
Retatrutide is the drug people ask about most and can legitimately get least, because every result below is phase 2 or earlier. The headline is real — 24.2% at 48 weeks, beating tirzepatide's ceiling — and so is the caveat: the phase 3 program is still running and nothing from it has been published. These ten papers are the entire evidence base.
10 ranked papers · Last verified 2026-08-16

Related Research on Ozempic

Deep-dive articles from our research desk with primary-source trial data, FDA label verification, and editorial analysis.

Is Zepbound a Semaglutide? Brand Names vs Molecules
No — Zepbound is tirzepatide, the same molecule as Mounjaro. Nine brand names cover five molecules, and knowing which is which decides your price and your coverage.
6 min read3 citations
Where to Inject a GLP-1, and Why Rotation Matters
Abdomen, front of thigh, or back of the upper arm — subcutaneous, never muscle. The instruction people skip is rotation, and skipping it can look exactly like the drug failing.
6 min read3 citations
The Cheapest Way to Get a GLP-1 Without Insurance
Compounded semaglutide runs $79 to $299 a month across 556 sellers; tirzepatide $99 to $399. The spread is four to one for the same molecule — here is what decides where you land.
8 min read3 citations
How to Get a GLP-1 Covered by Insurance
Coverage is decided in three steps, and most people give up at the wrong one. An exclusion and a denial are different things — only one of them is worth appealing.
8 min read3 citations
Do GLP-1 Patches Work? The Molecule Is Too Big
Skin stops molecules above roughly 500 daltons. Semaglutide weighs 4,114 and tirzepatide 4,813. No adhesive patch changes that, and no GLP-1 patch is FDA-approved.
7 min read4 citations
Is Microdosing Actually Cheaper? We Checked All 556 Sellers
31 sellers publish a microdose tier. The microdose is usually cheaper — but the two prices are quoted on different commitment terms, which is where the comparison breaks.
7 min read3 citations

Frequently Asked Questions

Sources & methodology — as of August 2026
  1. 1.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
  2. 2.SUSTAIN-6 Trial — Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (Marso SP et al.)— New England Journal of Medicine.PMID: 27633186.
  3. 3.ADA — Standards of Care in Diabetes (2025)— American Diabetes Association.
  4. 4.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  5. 5.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  6. 6.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Glossary

The words sellers use, defined. Tap any term.